A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency

Novo Nordisk

Status and phase

Completed

Phase 1

Conditions

Growth Hormone Deficiency in Children

Growth Hormone Disorder

Treatments

Drug: somatropin

Drug: somapacitan

Study type

Interventional

Funder types

Industry

Identifiers

NCT01973244

JapicCTI-142663 (Registry Identifier)

NN8640-4042

2013-000013-20 (EudraCT Number)

REec-2014-0688 (Registry Identifier)

U1111-1138-2206 (Other Identifier)

Details and patient eligibility

About

This trial is conducted in Europe and Asia. The aim of the trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of a single dose of long-acting growth hormone (NNC0195-0092, somapacitan) compared to daily dosing of Norditropin® SimpleXx® (somatropin) in children with growth hormone deficiency.

Enrollment

32 patients

Sex

All

Ages

6 to 13 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Confirmed diagnosis of GHD (growth hormone deficiency) as defined by two different GH (growth hormone) stimulation tests, peak GH level below or equal to 7.0 ng/ml. For children with three or more pituitary hormone deficiencies only one GH stimulation test will be needed. If in accordance with country specific practice, growth hormone deficiency can be defined by only one GH stimulation test, peak GH level below or equal to 7.0 ng/ml.
Pre-pubertal children at screening. Boys: Tanner stage 1 and age above or equal to 6 years and below 13 years. Girls: Tanner stage 1 and age above or equal to 6 years and below 12 years
Body weight above or equal to 16.0 kg and below or equal to 50.0 kg
Stable GH replacement treatment for at least 3 months

Exclusion criteria